Bal Pharma Limited
Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Az… Read more
Bal Pharma Limited (BALPHARMA) - Net Assets
Latest net assets as of September 2025: ₹783.30 Million INR
Based on the latest financial reports, Bal Pharma Limited (BALPHARMA) has net assets worth ₹783.30 Million INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹3.49 Billion) and total liabilities (₹2.71 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹783.30 Million |
| % of Total Assets | 22.42% |
| Annual Growth Rate | 4.71% |
| 5-Year Change | 45.08% |
| 10-Year Change | 41.45% |
| Growth Volatility | 8.87 |
Bal Pharma Limited - Net Assets Trend (2006–2025)
This chart illustrates how Bal Pharma Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bal Pharma Limited (2006–2025)
The table below shows the annual net assets of Bal Pharma Limited from 2006 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹774.04 Million | +11.76% |
| 2024-03-31 | ₹692.61 Million | +8.73% |
| 2023-03-31 | ₹637.02 Million | +8.91% |
| 2022-03-31 | ₹584.92 Million | +9.63% |
| 2021-03-31 | ₹533.54 Million | +17.68% |
| 2020-03-31 | ₹453.38 Million | -24.71% |
| 2019-03-31 | ₹602.21 Million | +0.03% |
| 2018-03-31 | ₹602.01 Million | +0.28% |
| 2017-03-31 | ₹600.31 Million | +9.70% |
| 2016-03-31 | ₹547.22 Million | -0.81% |
| 2015-03-31 | ₹551.68 Million | +10.23% |
| 2014-03-31 | ₹500.50 Million | +12.17% |
| 2013-03-31 | ₹446.18 Million | +11.39% |
| 2012-03-31 | ₹400.56 Million | +10.73% |
| 2011-03-31 | ₹361.75 Million | +1.16% |
| 2010-03-31 | ₹357.62 Million | -3.95% |
| 2009-03-31 | ₹372.35 Million | +6.29% |
| 2008-03-31 | ₹350.32 Million | +4.88% |
| 2007-03-31 | ₹334.02 Million | +3.41% |
| 2006-03-31 | ₹323.02 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bal Pharma Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 27310400000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹273.10 Million | 35.28% |
| Common Stock | ₹159.21 Million | 20.57% |
| Other Comprehensive Income | ₹22.07 Million | 2.85% |
| Other Components | ₹319.78 Million | 41.31% |
| Total Equity | ₹774.16 Million | 100.00% |
Bal Pharma Limited Competitors by Market Cap
The table below lists competitors of Bal Pharma Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tarmat Limited
NSE:TARMAT
|
$4.15 Million |
|
Skin Elements Ltd
AU:SKN
|
$4.15 Million |
|
Panatlântica S.A
SA:PATI3
|
$4.15 Million |
|
Elektrocieplownia Bedzin
WAR:BDZ
|
$4.15 Million |
|
Better Choice Company Inc
NYSE MKT:BTTR
|
$4.15 Million |
|
Agro Phos India Limited
NSE:AGROPHOS
|
$4.15 Million |
|
Asra Minerals Ltd
AU:ASR
|
$4.15 Million |
|
Trisula International Tbk
JK:TRIS
|
$4.15 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bal Pharma Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 692,943,000 to 774,159,000, a change of 81,216,000 (11.7%).
- Net income of 72,154,000 contributed positively to equity growth.
- Dividend payments of 19,105,000 reduced retained earnings.
- Share repurchases of 8,069,000 reduced equity.
- New share issuances of 1,412,000 increased equity.
- Other comprehensive income increased equity by 17,976,000.
- Other factors increased equity by 16,848,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹72.15 Million | +9.32% |
| Dividends Paid | ₹19.11 Million | -2.47% |
| Share Repurchases | ₹8.07 Million | -1.04% |
| Share Issuances | ₹1.41 Million | +0.18% |
| Other Comprehensive Income | ₹17.98 Million | +2.32% |
| Other Changes | ₹16.85 Million | +2.18% |
| Total Change | ₹- | 11.72% |
Book Value vs Market Value Analysis
This analysis compares Bal Pharma Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.25x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.05x to 1.25x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-03-31 | ₹32.31 | ₹66.33 | x |
| 2007-03-31 | ₹31.98 | ₹66.33 | x |
| 2008-03-31 | ₹32.63 | ₹66.33 | x |
| 2009-03-31 | ₹35.30 | ₹66.33 | x |
| 2010-03-31 | ₹33.97 | ₹66.33 | x |
| 2011-03-31 | ₹34.35 | ₹66.33 | x |
| 2012-03-31 | ₹38.04 | ₹66.33 | x |
| 2013-03-31 | ₹42.20 | ₹66.33 | x |
| 2014-03-31 | ₹45.43 | ₹66.33 | x |
| 2015-03-31 | ₹42.61 | ₹66.33 | x |
| 2016-03-31 | ₹42.65 | ₹66.33 | x |
| 2017-03-31 | ₹44.44 | ₹66.33 | x |
| 2018-03-31 | ₹45.86 | ₹66.33 | x |
| 2019-03-31 | ₹47.02 | ₹66.33 | x |
| 2020-03-31 | ₹36.99 | ₹66.33 | x |
| 2021-03-31 | ₹37.74 | ₹66.33 | x |
| 2022-03-31 | ₹38.72 | ₹66.33 | x |
| 2023-03-31 | ₹40.66 | ₹66.33 | x |
| 2024-03-31 | ₹43.84 | ₹66.33 | x |
| 2025-03-31 | ₹53.09 | ₹66.33 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bal Pharma Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.32%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.38%
- • Asset Turnover: 0.90x
- • Equity Multiplier: 4.34x
- Recent ROE (9.32%) is above the historical average (5.01%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 10.34% | 4.99% | 0.76x | 2.73x | ₹1.10 Million |
| 2007 | 6.04% | 2.87% | 0.78x | 2.71x | ₹-13.23 Million |
| 2008 | 8.16% | 3.33% | 0.79x | 3.11x | ₹-6.46 Million |
| 2009 | 8.04% | 2.89% | 0.85x | 3.26x | ₹-7.31 Million |
| 2010 | -4.00% | -1.35% | 0.86x | 3.47x | ₹-50.05 Million |
| 2011 | 1.13% | 0.36% | 0.84x | 3.74x | ₹-32.10 Million |
| 2012 | 9.38% | 2.69% | 0.99x | 3.52x | ₹-2.49 Million |
| 2013 | 9.60% | 2.90% | 0.99x | 3.36x | ₹-1.78 Million |
| 2014 | 10.13% | 2.84% | 1.16x | 3.09x | ₹673.43K |
| 2015 | 6.57% | 1.94% | 1.14x | 2.97x | ₹-18.92 Million |
| 2016 | 2.56% | 0.71% | 0.94x | 3.84x | ₹-40.85 Million |
| 2017 | 3.15% | 0.87% | 0.99x | 3.66x | ₹-43.13 Million |
| 2018 | 4.28% | 1.33% | 0.83x | 3.87x | ₹-37.17 Million |
| 2019 | 5.68% | 1.68% | 0.86x | 3.92x | ₹-28.76 Million |
| 2020 | -23.31% | -7.14% | 0.72x | 4.55x | ₹-174.61 Million |
| 2021 | 8.85% | 1.92% | 1.03x | 4.48x | ₹-6.16 Million |
| 2022 | 9.57% | 2.00% | 1.08x | 4.44x | ₹-2.51 Million |
| 2023 | 4.03% | 0.85% | 0.97x | 4.91x | ₹-38.07 Million |
| 2024 | 10.67% | 2.18% | 1.06x | 4.61x | ₹4.63 Million |
| 2025 | 9.32% | 2.38% | 0.90x | 4.34x | ₹-5.26 Million |
Industry Comparison
This section compares Bal Pharma Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $12,445,167,922
- Average return on equity (ROE) among peers: 14.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bal Pharma Limited (BALPHARMA) | ₹783.30 Million | 10.34% | 3.46x | $4.15 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |